Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis.
Background: Epidemiological studies investigating the use of proton pump inhibitors (PPI) on the risk of liver cancer and/or mortality among persons with chronic liver disease (CLD) have reported conflicting results. We conducted a systematic review and meta-analysis to determine the impact of PPI u...
| Published in: | European Journal of Clinical Pharmacology Vol. 76; no. 6; pp. 851 - 867 |
|---|---|
| Main Authors: | , , , , |
| Format: | research systematic review tables/charts Journal Article |
| Published: |
Springer Nature
Jun2020
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143359718&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 143359718 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Jun2020 vid: 76 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 143359718 143359718 143359718 10.1007/s00228-020-02854-8 143359718 ppf: 851 ppct: 16 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. aug: au: Song, Hyun Jin Jiang, Xinyi Henry, Linda Nguyen, Mindie H. Park, Haesuk affil: Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1225 Center Drive, 32610, Gainesville, FL, USA sug: subj: Liver Diseases Drug Therapy Chronic Disease Drug Therapy Proton Pump Inhibitors Adverse Effects Liver Neoplasms Risk Factors Liver Diseases Mortality Risk Assessment Human Systematic Review Meta Analysis Medline Embase Cochrane Library Confidence Intervals Relative Risk Descriptive Statistics Carcinoma, Hepatocellular Risk Factors ab: Background: Epidemiological studies investigating the use of proton pump inhibitors (PPI) on the risk of liver cancer and/or mortality among persons with chronic liver disease (CLD) have reported conflicting results. We conducted a systematic review and meta-analysis to determine the impact of PPI use on liver cancer and/or death among patients with CLD. Methods: The core databases including MEDLINE, EMBASE, and Cochrane library were searched through January 2020. We included studies, evaluating the association between PPIs and liver cancer or mortality among patients with CLD including randomized controlled, nonrandomized controlled, and observational studies. We used inverse-variance random-effects models to estimate the pooled relative risk (RR) and 95% confidence interval (CI) for liver cancer or mortality. Results: Eleven studies including 173,894 patients were selected. In three studies, individuals with CLD who used PPIs had a 67% greater risk of developing hepatocellular carcinoma (HCC) compared to nonusers (RR, 1.67; 95% CI, 1.12–2.50; I2 = 92%). Combining data from the eight studies relating PPI to overall mortality, we observed a 57% increased risk of mortality in PPI users with CLD compared to CLD nonusers (RR: 1.57; 95% CI, 1.24–1.99; I2 = 69%). Conclusion: PPI use was associated with an increased risk of HCC and mortality in patients with CLD suggesting that PPI prescriptions in patients with CLD should be considered carefully. pubtype: Academic Journal doctype: meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|